Evidence map›Paper›PMID 31010476›Full record

ArticleKidney international2019

Effect of thiazolidinedione therapy on the risk of uric acid stones.

John R Asplin, David S Goldfarb

Abstract readComment
PubMed Publisher
In one paragraph

Article in Kidney international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Breaking the Cycle of Recurrent Calcium Stone Disease.Advances in kidney disease and health · 2023
    Review
  5. Update on Uric Acid and the Kidney.Current rheumatology reports · 2022
    Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

John R AsplinLitholink Corporation, Laboratory Corporation of America Holdings, Chicago, Illinois, USA.
David S GoldfarbNephrology Section, VA New York Harbor Healthcare System, New York, New York, USA; Nephrology Division, New York University School of Medicine, New York, New York, USA. Electronic address: david.goldfarb@va.gov.
LabCorp (United States) · USVA NY Harbor Healthcare System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most important variable leading to uric acid stones is low urine pH. Major causal conditions associated with low urine pH are metabolic syndrome and diabetes. In the study by Maalouf et al., treatment of uric acid stone formers with pioglitazone led to small but significant increases in urine pH. Pioglitazone will not supplant alkali administration to prevent uric acid stones, but the study helps confirm that insulin resistance is an important cause of low urine pH that causes uric acid stones.

Indexed as

Kidney CalculiThiazolidinedionesAcidsHumansPioglitazoneUric AcidAcidsPioglitazoneThiazolidinedionesUric Acid

Identifiers

PMID31010476
OpenAlexW2940412942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.